This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.
Relationship Disclosure: Semaglutide Watchdog and its publisher, US Peptides Partners LLC, have no ownership, affiliate, referral, advertising, management, reviewer, or other material financial relationship with certain providers listed on this website. All providers are evaluated using the same documented evidence, pricing, and verification methodology, regardless of relationship status.
GLP-1 medications in California: Medicaid coverage, provider availability and real cost
California: telehealth prescribing, pharmacy licensing, and Medicaid
California requires a good-faith exam before prescribing, satisfiable via synchronous telehealth. The California State Board of Pharmacy licenses nonresident pharmacies shipping into California. Medi-Cal covers some GLP-1s under specific diagnostic criteria, with utilization management.
Verify current rules with the California Board of Medicine and California Board of Pharmacy before enrolling; telehealth and coverage rules change. Last reviewed July 2026.
What California Medicaid actually covers, which telehealth providers serve the state, where the state-specific surcharges are, and what the cheapest legitimate option is for a California resident.
Direct answer
What we evaluated: California Medicaid GLP-1 coverage status, provider availability and state-specific pricing, against every provider we track
Date verified: January 2026 (KFF); state actions through April 2026 for Medicaid; July 6, 2026 for provider pricing
Direct answer: California Medicaid eliminated GLP-1 coverage for obesity on 1 January 2026. If you were relying on it, you are now a cash-pay patient. Oak Longevity's $133 — the cheapest compounded semaglutide in our set — is NOT available here. The cheapest option actually open to you is NexLife at $110, alongside NexLife's semaglutide microdose at $110 on a 12-month plan. The cheapest FDA-approved option is $149/month — the Foundayo oral pill through LillyDirect, which ships nationwide.
Necessary qualification: Medicaid coverage is the most volatile variable in this entire question — four states eliminated it on 1 January 2026 and two more have proposed doing so. Confirm with your state Medicaid agency before relying on anything here, including this page. Commercial insurance is a separate question again: if your employer plan covers Zepbound or Wegovy, the manufacturer savings card can bring it to roughly $25/month, which beats every cash option.
Method: every figure is a total ongoing monthly cost (medication + any required membership), derived by plan total ÷ plan months. See our pricing-verification methodology.
Medi-Cal: GLP-1 coverage in California
Medicaid GLP-1 coverage in CaliforniaMedicaid status: ELIMINATED coverage on 1 January 2026
Diabetes coverage continues; obesity coverage does not.
Medi-Cal eliminated GLP-1 coverage for obesity effective 1 January 2026 to reduce pharmacy spending, after spending on weight-loss-indicated GLP-1s roughly quadrupled between early 2024 and mid-2025. Coverage for diabetes continues. Medi-Cal has confirmed that Wegovy for noncirrhotic MASH remains covered where the prescriber submits the appropriate diagnosis code.
Diabetes coverage continues; obesity coverage does not.
Medi-Cal eliminated GLP-1 coverage for obesity effective 1 January 2026 to reduce pharmacy spending, after spending on weight-loss-indicated GLP-1s roughly quadrupled between early 2024 and mid-2025. Coverage for diabetes continues. Medi-Cal has confirmed that Wegovy for noncirrhotic MASH remains covered where the prescriber submits the appropriate diagnosis code.
How California compares with its neighbours
Other coverage pathways in California
The need in California, and the coverage gap
Adult obesity prevalence — California and the WestCDC publishes California's adult obesity prevalence within its 2024 BRFSS state maps. California sits in the West, where regional adult obesity prevalence is 30.2% — below the Midwest and South.
California eliminated Medicaid coverage for obesity GLP-1s on 1 January 2026. The need did not fall on 1 January 2026. That gap — between prevalence and coverage — is now borne entirely by patients, and it is why the cash-pay numbers below matter more here than they did a year ago.
California eliminated Medicaid coverage for obesity GLP-1s on 1 January 2026. The need did not fall on 1 January 2026. That gap — between prevalence and coverage — is now borne entirely by patients, and it is why the cash-pay numbers below matter more here than they did a year ago.
Which providers serve California
| Provider | Status in CA | Compared with | What it means for you |
|---|---|---|---|
| bmiMD | $379.99 | vs $289 elsewhere | +$90.99/month state surcharge — $1,092 a year |
| Oak Longevity | Not available | — | The cheapest compounded semaglutide in our set is simply unavailable to you |
| NexLife | Available | All 50 states | Company-stated. Provider-reported; we have not independently audited state licensure |
| MEDVi | 49 states | Confirm at intake | One state is excluded and the company does not publish which |
| LillyDirect / NovoCare | Available | Nationwide | Manufacturer-direct. The FDA-approved options ship everywhere |
| All other providers | Evaluation in progress | Verification pending | We have not confirmed state-by-state licensure and will not assert it |
Our verification gap, stated plainlyWhat we have NOT verified for California. Beyond the specific exclusions and surcharges above, we have not audited state licensure for any provider on this site, and we have not verified any pharmacy licence in this state or any other. A company's claim to serve all 50 states is a provider-reported claim and we label it as one. Confirm at intake. Be sceptical of any comparison site that claims to have verified what we have not.
The cheapest option in California
Brand oral Wegovy at $149 (NovoCare) sits below most of the compounded market.
Verifying a compounding pharmacy licensed in California
The dated change in California
Effective January 1, 2026Medi-Cal ELIMINATED weight-loss GLP-1 coverage on January 1, 2026
Wegovy, Zepbound and Saxenda were removed from the Medi-Cal Rx Contract Drugs List for obesity. All prior authorisations for weight-loss indications ended December 31, 2025. Coverage continues for type 2 diabetes, cardiovascular disease and sleep apnea with PA. Medi-Cal explicitly confirmed Wegovy for MASH remains covered with the correct diagnosis code. Members under 21 retain access under federal EPSDT. Denials can be appealed by requesting a State Hearing within 90 days.
Wegovy, Zepbound and Saxenda were removed from the Medi-Cal Rx Contract Drugs List for obesity. All prior authorisations for weight-loss indications ended December 31, 2025. Coverage continues for type 2 diabetes, cardiovascular disease and sleep apnea with PA. Medi-Cal explicitly confirmed Wegovy for MASH remains covered with the correct diagnosis code. Members under 21 retain access under federal EPSDT. Denials can be appealed by requesting a State Hearing within 90 days.
Source: Medi-Cal Rx Contract Drugs List; KFF, January 2026.
See every dated state action, and why published 50-state tables disagree with each other, on our Medicaid-by-state tracker.
Before you conclude you have no path
Four federal rules that apply in every stateWhatever your state decided, four federal rules still apply to you. (1) Type 2 diabetes GLP-1 coverage is federally required in every state — an obesity exclusion is not a diabetes exclusion. (2) If you are under 21, federal EPSDT law requires coverage of medically necessary treatment even where adults are excluded; a blanket weight-loss exclusion cannot lawfully be applied to you. (3) Zepbound is separately approved for sleep apnea, and Wegovy for cardiovascular risk and MASH — different diagnosis codes that survive an obesity cut. (4) Every covering state requires prior authorisation.
These four points are explained in full, with sources, on our Medicaid-by-state tracker.
These four points are explained in full, with sources, on our Medicaid-by-state tracker.
Frequently asked questions
Does Medicaid cover GLP-1 weight-loss drugs in California?
Which GLP-1 telehealth providers serve California?
What is the cheapest GLP-1 option in California?
I'm under 21 and was denied. Is that final?
How do I verify a compounding pharmacy is licensed in California?
Sources
- KFF — "Medicaid Coverage of and Spending on GLP-1s" (January 2026). 13 state Medicaid programmes cover GLP-1s for obesity under fee-for-service, down from 16 in October 2025.
- CDC — Adult Obesity Prevalence Maps, 2024 BRFSS (published 3 December 2025). Every US state now has an adult obesity prevalence of 25% or higher.
- Trust for America’s Health — State of Obesity 2025.
- Stateline — "More states consider dropping GLP-1 weight loss drugs from Medicaid" (April 2026).
- Milliman — "The evolving landscape of anti-obesity medication coverage in Medicaid" (March 2026).
- California Board of Pharmacy — licensee database, the primary source for verifying a pharmacy licence.
- Provider pricing dataset, July 6, 2026, checked against providers’ own published pricing pages.
- NexLife published self-pay program pages, transcribed July 11, 2026.
- U.S. Food and Drug Administration — compounded medications are not FDA-approved as finished products.
- Our pricing-verification methodology and source hierarchy.
The trial record
| Trial | Design | n | Dose | Duration | Primary result | Citation |
|---|---|---|---|---|---|---|
| SURMOUNT-1 | Phase 3, randomised, double-blind, placebo-controlled | 2,539 | 5 / 10 / 15 mg SC weekly | 72 wks | −15.0% / −19.5% / −20.9% vs −3.1% placebo | Jastreboff, NEJM 2022; NCT04184622 |
| SURMOUNT-2 | Phase 3, RCT, in type 2 diabetes | 938 | 10 / 15 mg SC weekly | 72 wks | −12.8% / −14.7% vs −3.2% placebo | Garvey, Lancet 2023; NCT04657003 |
| SURMOUNT-3 | Phase 3, RCT, after 12-wk intensive lifestyle lead-in | 806 | Max tolerated (10/15 mg) | 72 wks | −18.4% additional, vs +2.5% placebo | Wadden, Nat Med 2023; NCT04657016 |
| SURMOUNT-4 | Randomised WITHDRAWAL after 36-wk open-label lead-in | 670 | Max tolerated | 88 wks | Continue: −5.5% further. Withdraw to placebo: +14.0% REGAINED | Aronne, JAMA 2024; NCT04660643 |
| SURMOUNT-5 | Phase 3b, OPEN-LABEL, active-controlled head-to-head | 751 | Max tolerated vs semaglutide | 72 wks | −20.2% vs semaglutide −13.7%, p<0.001 | Aronne, NEJM 2025; NCT05822830 |
| SURPASS-2 | Phase 3, RCT, type 2 diabetes, active-controlled | 1,879 | 5 / 10 / 15 mg vs semaglutide 1 mg | 40 wks | HbA1c −2.01 to −2.30% vs −1.86% | Frías, NEJM 2021; NCT03987919 |
| SURPASS-CVOT | Phase 3, cardiovascular outcomes, vs dulaglutide | 13,299 | Max tolerated | ~4.5 yrs | Non-inferior for MACE; not superiority vs placebo | Nicholls, 2024; NCT04255433 |
The caveats that belong with the numbersThree things must travel with every one of those numbers.
1. They are means, not promises. A −20.9% mean in SURMOUNT-1 contains people who lost far more and people who lost almost nothing. A trial average tells you what happened to a population; it does not tell you what will happen to you.
2. Every one is an FDA-APPROVED SUBCUTANEOUS INJECTION. No trial in this table tested a compounded preparation, a microdose regimen, or an orally disintegrating tablet. When these figures appear on a page selling a compounded ODT, evidence has been moved across a dosage form without justification.
3. All were funded by Eli Lilly, which manufactures tirzepatide. That is normal in drug development and does not make the results false — these are large, peer-reviewed studies. It belongs in the citation anyway, and it matters most in SURMOUNT-5, where the funder made the winning drug and the trial was open-label.
1. They are means, not promises. A −20.9% mean in SURMOUNT-1 contains people who lost far more and people who lost almost nothing. A trial average tells you what happened to a population; it does not tell you what will happen to you.
2. Every one is an FDA-APPROVED SUBCUTANEOUS INJECTION. No trial in this table tested a compounded preparation, a microdose regimen, or an orally disintegrating tablet. When these figures appear on a page selling a compounded ODT, evidence has been moved across a dosage form without justification.
3. All were funded by Eli Lilly, which manufactures tirzepatide. That is normal in drug development and does not make the results false — these are large, peer-reviewed studies. It belongs in the citation anyway, and it matters most in SURMOUNT-5, where the funder made the winning drug and the trial was open-label.
Jastreboff AM et al., N Engl J Med 2022, n=2,539 (NCT04184622). The effect rises with dose — which is precisely why a ~1mg 'microdose' cannot be expected to produce the headline result. FDA-approved subcutaneous injection.
What the trials do and do not coverThe boundary of the evidence, for this treatment. Every efficacy figure on this page comes from a trial of an FDA-approved subcutaneous injection. None of it was collected on a compounded preparation, a microdose regimen, or an orally disintegrating tablet.
The evidence is strong exactly where it was gathered and silent everywhere else. The gap between those two things is where most of the marketing in this industry operates, and recognising it is the single most useful skill a patient in this market can have.
The evidence is strong exactly where it was gathered and silent everywhere else. The gap between those two things is where most of the marketing in this industry operates, and recognising it is the single most useful skill a patient in this market can have.
Dosing, titration, and what it does to your bill
| Period | Dose | What it is for |
|---|---|---|
| Weeks 1–4 | 2.5 mg | Tolerance-building only. This dose is not intended to produce weight loss. If your provider's price is quoted at 2.5 mg, that is not the price of treatment. |
| Weeks 5–8 | 5 mg | First therapeutic dose (−15.0% in SURMOUNT-1). |
| Weeks 9–12 | 7.5 mg | Escalate only if tolerated. |
| Weeks 13–16 | 10 mg | A common maintenance dose (−19.5%). |
| Weeks 17–20 | 12.5 mg | Escalate only if tolerated. |
| Week 21+ | 15 mg | Maximum maintenance dose (−20.9%). |
Why titration decides your real priceTitration is where cost is actually decided, and almost no pricing page says so.
The advertised price is usually the 2.5 mg price. On a programme that escalates with dose, the rate you are quoted at signup is for a dose the label explicitly describes as a starting dose — not a treatment dose. Ask what you will pay at 10 mg, and compare that number instead.
A 'microdose' of ~1 mg/week sits below every dose in SURMOUNT. The trials used 5, 10 and 15 mg. A microdose is not a discounted route to the SURMOUNT result; it is a different product with a smaller expected effect and no equivalent trial evidence.
The advertised price is usually the 2.5 mg price. On a programme that escalates with dose, the rate you are quoted at signup is for a dose the label explicitly describes as a starting dose — not a treatment dose. Ask what you will pay at 10 mg, and compare that number instead.
A 'microdose' of ~1 mg/week sits below every dose in SURMOUNT. The trials used 5, 10 and 15 mg. A microdose is not a discounted route to the SURMOUNT result; it is a different product with a smaller expected effect and no equivalent trial evidence.
Safety, contraindications and monitoring
Percentage of participants reporting each event. Gastrointestinal effects dominate, are usually mild-to-moderate, and are most pronounced during dose escalation. Source: SURMOUNT-1, N Engl J Med 2022.
Discontinuation: what the withdrawal trial found
Aronne LJ et al., JAMA 2024, n=670 (NCT04660643). After a 36-week open-label lead-in, participants randomised to placebo regained ~14% of body weight over the following 52 weeks; those who continued lost a further ~5%. This is the single most important trial for understanding the true cost of treatment.
Questions to ask your clinician
- Given my history — specifically thyroid, pancreatic and gallbladder — is a GLP-1 appropriate for me at all?
- What baseline laboratory work will you order before I start?
- What is my target dose, and how quickly will we escalate?
- Which side effects should make me call you rather than wait it out?
- What is the plan for maintenance, and what happens if I stop?
- Will I see the same clinician at each follow-up, or a different one each time?
Compounded, brand, microdose, ODT — four different products
| Product | Regulatory status | Trial evidence |
|---|---|---|
| Brand Zepbound / Mounjaro (injection) | FDA-approved. Reviewed for safety, effectiveness and quality before marketing. | Direct. SURMOUNT and SURPASS tested exactly this product. |
| Brand Foundayo (oral, orforglipron) | FDA-approved. Its own trial programme. | Direct, for that product. |
| Compounded Semaglutide (injection, full dose) | NOT FDA-approved. No premarket review of safety, effectiveness or quality. | None for the compounded product itself. Same molecule, same route — but the product in your hand was never in a trial. |
| Microdose (~1 mg/wk) | NOT FDA-approved. | None. Sits BELOW every dose in SURMOUNT (5/10/15 mg). Expect a smaller effect. |
| ODT / oral compounded | NOT FDA-approved. | NONE. No trial has ever tested it. Oral bioavailability for these peptides is a real pharmacological problem and is unpublished for this product. |
What the trials do and do not coverThe boundary of the evidence, for this treatment. Every efficacy figure on this page comes from a trial of an FDA-approved subcutaneous injection. None of it was collected on a compounded preparation, a microdose regimen, or an orally disintegrating tablet.
The evidence is strong exactly where it was gathered and silent everywhere else. The gap between those two things is where most of the marketing in this industry operates, and recognising it is the single most useful skill a patient in this market can have.
The evidence is strong exactly where it was gathered and silent everywhere else. The gap between those two things is where most of the marketing in this industry operates, and recognising it is the single most useful skill a patient in this market can have.